Idorsia Ltd
SIX:IDIA
Idorsia Ltd
SIX:IDIA
Price:
2.312 CHF
7.04%
Market Closed
Updated:
May 14, 2024
Section:
Relative Value
The Relative Value of one
IDIA
stock under the Base Case scenario is
8.1
CHF.
Compared to the current market price of 2.312 CHF,
Idorsia Ltd
is
Undervalued by 71%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IDIA
Relative Value
Base Case
8.1
CHF
Undervaluation 71%
Valuation Multiples
Multiples Across Competitors
IDIA Competitors Multiples
Idorsia Ltd Competitors
Idorsia Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Idorsia Ltd
SIX:IDIA
|
412.9m CHF | 2.2 | -1.1 | -1.8 | -1.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 5.2 | 59.1 | 12.8 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 5.6 | 44 | 18.6 | 30.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 11.2 | 30.6 | 24.7 | 25.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.7B USD | 8.2 | 27.9 | 22.6 | 25 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.2B USD | 3.1 | 173.9 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48.1B USD | 9.3 | -8.1 | -8.8 | -7.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 3.4 | 28.1 | 14.3 | 17.9 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.5T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
